Albireo is an independent Swedish biotechnology company based in Gothenburg, with broad experience in the GI area and a pipeline of programmes for underserved markets.
Albireo was spun-out of AstraZeneca in February 2008. Albireo is financed by a syndicate of growth capital firms, led by Phase4 Ventures and supported by other specialist investors in the healthcare markets including TVM Capital and Scottish Widows Investment Partnership. The company has raised $40m in a Series A financing round.
We are focused on developing novel therapies that address unmet medical needs in the GI area. Specifically, we are concentrating on generating significant clinical data for our lead programme in chronic constipation, and on progressing our pre-clinical assets into the clinic. We will achieve this by:
- Exploiting our expertise and experience in translational research
- Drawing on our extensive knowledge and track record in drug development
- Leveraging our extensive network in the scientific, clinical, academic and pharma communities
- Managing all our internal and external capabilities in a cost effective way